GlassScriptPhysician profile
Selby B Oberton
NPI 1437395415
$4,750.95
in general payments reported to CMS, 2019-2025
30 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $241 · 2021: $614 · 2022: $417 · 2023: $1,007 · 2024: $727 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,926.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $924.06 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Abiomed | $519.26 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $468.43 | 2020-2025 | Opsumit, Uptravi |
| Impulse Dynamics (USA) INC. | $397.12 | 2022-2025 | Optimizer, Optimizer |
| Astrazeneca Pharmaceuticals LP | $246.69 | 2020-2025 | Wainua, Farxiga |
| Cvrx, INC. | $223.57 | 2024 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $222.07 | 2022-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $164.17 | 2021-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.26 | 2024-2025 | Jardiance |
| Amgen INC. | $149.05 | 2019-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $141.77 | 2021-2025 | |
| Akcea Therapeutics, INC. | $139.34 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.97 | 2023-2025 | |
| Medtronic Vascular, INC. | $118.71 | 2019 | |
| Bridgebio Pharma, INC. | $114.96 | 2025 | Attruby |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $95.63 | 2023-2025 | Tyvaso, Tyvaso |
| Scpharmaceuticals INC. | $77.51 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $61.20 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $60.89 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $52.61 | 2023-2025 | Camzyos, Eliquis |
| Pfizer INC. | $48.45 | 2021-2024 | |
| Daiichi Sankyo INC. | $43.84 | 2023-2024 | Injectafer |
| Kestra Medical Technology Services, INC. | $38.82 | 2025 | Assure Wcd |
| Analog Devices INC. | $32.67 | 2025 | Sensinel Cpm Wearable |
| Irhythm Technologies, INC. | $30.48 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $21.60 | 2022 | |
| Novo Nordisk INC | $17.82 | 2025 | Wegovy |
| Mannkind Corporation | $16.05 | 2025 | |
| Heartflow, INC. | $15.73 | 2019 | |
| Boston Scientific Corporation | $13.22 | 2024 | Lux-Dx Insertable Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selby Oberton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.